拨康视云-B(02592)股东将股票存入建设亚洲 存仓市值1.94亿港元

智通财经
Mar 19

智通财经APP获悉,香港联交所最新资料显示,3月18日,拨康视云-B(02592)股东将股票存入建设亚洲,存仓市值1.94亿港元,占比11.23%。

2月16日,拨康视云发布公告,公司于美利坚合众国(美国)特拉华州注册成立的全资附属公司 ADS Therapeutics LLC (ADS USA),已完成有关于2025年12月12日向美国食品及药物管理局(美国药管局)提交的CBT-199(一种由本集团开发的潜在同类最佳眼科候选药物)新药临床试验申请(新药临床试验申请)的审查期。由于美国药管局未发出任何临床试验暂停令,新药临床试验申请现已生效,临床试验被认定为可安全推进。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10